Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"During the quarter, we completed our landmark partnership deal with Eli Lilly and Company," said Kevin Giese, President and CEO of BioMS Medical. "We now look forward to multiple clinical milestones for dirucotide (MBP8298) over the next 24 months. In the near-term, the Data Safety Monitoring Board for our MAESTRO-01 pivotal trial will review data from the first 200 patients in the trial and recommend whether the trial should continue. A positive outcome from this review, anticipated in the third quarter of 2008, is expected to trigger a milestone payment from our new partner."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe

evaluating dirucotide (MBP8298) for the treatment of secondary

progressive MS (SPMS). On January 22, 2007, BioMS announced that the

trial had completed full recruitment of 611 patients at 47 trial

sites in 10 countries. Patients are administered either dirucotide

(MBP8298) or placebo every six months for a period of two years. To

date, there have been eight positive safety reviews from the

Data Safety Monitoring Board (DSMB).

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... market analysis and premium industry insights on the global resorcinol industry. The report ... collective study of vivid market scenarios and analysis of primary and secondary inputs ...
(Date:7/30/2015)... ... 2015 , ... Ralco is honored to announce that it is the primary ... held August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where ... impacts their daily lives. This unique exhibit also features a birthing center for fair ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... Ill. --- Imagine having one polymer and one small molecule ... which you can grow human stem cells, creating a sort ... therapy, could cloak the stem cells from the human bodys ... the stem cells to do their work. , Futuristic" Only ...
... FRANKLIN LAKES, N.J., March 27 BD (Becton,Dickinson ... global medical technology,company, and Direct Relief International, a ... joint volunteer,initiative to strengthen healthcare in Ghana. A ... to Ghana for three weeks and work side-by-side,with ...
... March 27 /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware),is ... recently completed pilot,clinical trial for its new ... operating company IntelliPharmaCeutics,Corp. of Toronto ("IntelliPharmaCeutics" or ... patent applications for its novel ReXista(TM) abuse ...
Cached Biology Technology:Self-assembled materials form mini stem cell lab 2Self-assembled materials form mini stem cell lab 3Self-assembled materials form mini stem cell lab 4BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 3IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 2IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 3
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Little attention has been paid to whether systematic ... ?and thus easily ameliorated through market incentives ?or ... spite of experience. In a groundbreaking new study ... extend this question across species, exploring how a ...
... at the University of Warwick are examining a way ... potential anti-cancer drugs that are difficult to create synthetically ... naturally produce antibiotics called prodiginines. , This group ... can be used to target and kill cancer cells. ...
... prospect of a paycheck, good grade, or promotion ... identified the brain circuitry responsible for such reward-motivated ... 4, 2006, Neuron, Alison Adcock and colleagues report ... reward-related brain regions "alert" the brain's learning and ...
Cached Biology News:The brain's motivation station 2
... consists of two components used for alkaline ... ES cell-specific antibodies required to perform 100 ... become the subject of extensive investigation recently, ... because they raise several fundamental issues concerning ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... For use as a carrier ... precipitation. Physical form: Solution in ... 7.4, 1 mM EDTA Preparation ... Concentration: 10 ...
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
Biology Products: